Amobarbital

PreclinicalSmall molecule

TTongji Hospital

Amobarbital is one of 25 small molecule programs targeting Osteoarthritis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteoarthritisTerminated

Cardiopulmonary BypassCompleted

OsteoarthritisPreclinical

Terminated

Cardiopulmonary BypassPreclinical

Completed

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Epidiolex

Jazz Pharmaceuticals

Preclinical

4 2

Ilaris

Novartis

Preclinical

2 3

Toradol

Roche

Preclinical

1 4

Voltaren

CCerimon Pharmaceuticals

Preclinical

4 5

Glucophage

Boehringer Ingelheim

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 7

Chirocaine

PPurdue Pharma LP

Preclinical

1 8

Lunesta

Akero Therapeutics

Preclinical

1 9

Catapres

Boehringer Ingelheim

Preclinical

1 10

Paracetamol

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adverse Reaction1 trial

Effect of Amobarbital Sodium Combined With Low-dose Propofol on Hemodynamics During Induction and Perioperative Adverse Reactions

Not yet recruiting·TTongji Hospital·Phase 4·NCT06385756·96 enrolled

Osteoarthritis1 trial

Translating Metabolic Responses to Mechanical Insult Into Early Interventions to Prevent PTOA

Terminated·JJ L Marsh·Preclinical·NCT04589611·5 enrolled

Cardiopulmonary Bypass1 trial

The Effect of Amobarbital on Myocardial Protection and Prognosis in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass

Completed·TTongji Hospital·Preclinical·NCT06757868·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Amobarbital. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Amobarbital compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Amobarbital. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tongji Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TTongji Hospital

Amobarbital

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Adverse Reaction1 trial

Osteoarthritis1 trial

Cardiopulmonary Bypass1 trial

References

Drug Info

Quick Facts

Related News